EA202091615A1 - Интраназальные составы на основе эпинефрина и способы лечения заболевания - Google Patents

Интраназальные составы на основе эпинефрина и способы лечения заболевания

Info

Publication number
EA202091615A1
EA202091615A1 EA202091615A EA202091615A EA202091615A1 EA 202091615 A1 EA202091615 A1 EA 202091615A1 EA 202091615 A EA202091615 A EA 202091615A EA 202091615 A EA202091615 A EA 202091615A EA 202091615 A1 EA202091615 A1 EA 202091615A1
Authority
EA
Eurasian Patent Office
Prior art keywords
epinephrine
methods
treating
disease
formulations based
Prior art date
Application number
EA202091615A
Other languages
English (en)
Inventor
Ричард Лоуэнтал
Эдвард Т. Маджио
Роберт Г. Белл
Пратик Шах
Original Assignee
Аегис Терапьютикс, Ллс
Арс Фармасьютикалс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67548575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202091615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аегис Терапьютикс, Ллс, Арс Фармасьютикалс Инк. filed Critical Аегис Терапьютикс, Ллс
Publication of EA202091615A1 publication Critical patent/EA202091615A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Abstract

Представлены лекарственные препараты, выполненные с возможностью назальной доставки, содержащие составы с эпинефрином, и устройства, содержащие такие составы. Также представлены способы лечения анафилаксии с помощью продуктов на основе эпинефрина.
EA202091615A 2018-12-21 2019-02-06 Интраназальные составы на основе эпинефрина и способы лечения заболевания EA202091615A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784057P 2018-12-21 2018-12-21
PCT/US2019/016918 WO2019157099A1 (en) 2018-02-06 2019-02-06 Intranasal epinephrine formulations and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
EA202091615A1 true EA202091615A1 (ru) 2021-03-05

Family

ID=67548575

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091615A EA202091615A1 (ru) 2018-12-21 2019-02-06 Интраназальные составы на основе эпинефрина и способы лечения заболевания

Country Status (4)

Country Link
US (8) US20190269780A1 (ru)
JP (2) JP6941224B2 (ru)
EA (1) EA202091615A1 (ru)
WO (1) WO2019157099A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
AU2021217164A1 (en) * 2020-02-05 2022-08-25 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US20210283074A1 (en) * 2020-03-16 2021-09-16 Nasus Pharma Ltd. Polymeric Compositions for Intranasal Administration
KR20230005133A (ko) * 2020-04-30 2023-01-09 퍼듀 퍼머 엘피 긴급 구조용 조성물 및 방법
EP4146246A1 (en) * 2020-05-04 2023-03-15 Amphastar Pharmaceuticals, Inc. Safe use of bile acids and their salts as enhancers for nasal delivery of pharmaceuticals
WO2021225973A1 (en) * 2020-05-04 2021-11-11 Amphastar Pharmaceuticals, Inc. Naloxone pharmaceutical formulations for intranasal (in) delivery
MD3962455T2 (ro) 2020-05-18 2022-12-31 Orexo Ab Compoziție farmaceutică nouă pentru livrare de medicamente
US11439651B2 (en) * 2020-10-18 2022-09-13 CoFix-RX, LLC Nasal spray composition for COVID-19 and SARS and method of forming the same
WO2022129069A1 (en) * 2020-12-17 2022-06-23 Philip Morris Products S.A. Pharmaceutical composition comprising epinephrine for aerosol administration
US11617716B2 (en) * 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003971A (en) 1908-11-14 1911-09-26 United Shoe Machinery Ab Sole-pressing machine.
US1026540A (en) 1911-05-31 1912-05-14 C E Cole Washing-machine.
US3547828A (en) 1968-09-03 1970-12-15 Rohm & Haas Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
JPH01151528A (ja) 1987-12-08 1989-06-14 Taiho Yakuhin Kogyo Kk 経粘膜吸収促進剤
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
DE69214346T2 (de) 1991-05-16 1997-03-06 Kao Corp Gegen mikrobielle Aktivität stabile wässerige Alkylglycosidlösung
WO1994005262A1 (en) 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
WO1995011042A1 (fr) 1993-10-21 1995-04-27 Hisamitsu Pharmaceutical Co., Inc. Composition administree par voie nasale et preparation contenant celle-ci
SE9404196D0 (sv) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
CZ288146B6 (en) 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
CA2374877C (en) 1999-06-16 2004-04-13 Nastech Pharmaceutical Co., Inc. Pharmaceutical formulations and methods comprising intranasal morphine
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU783208B2 (en) 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6551578B2 (en) 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US20040248846A1 (en) 2003-04-22 2004-12-09 Nastech Pharmaceutical Company Inc. Intranasal administration of triptans
GB0310919D0 (en) 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1656102A2 (en) 2003-08-21 2006-05-17 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20060046969A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20120021980A1 (en) 2004-08-25 2012-01-26 Aegis Therapeutics, Inc. Compositions for drug administration
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
TW200817049A (en) 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
EP3669878A1 (en) * 2006-08-10 2020-06-24 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
WO2009121039A2 (en) 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
CN102933198B (zh) 2009-09-25 2015-10-07 雷迪博士实验室有限公司 包含曲普坦化合物的制剂
WO2011139838A2 (en) 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Intranasal formulations
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014127015A1 (en) 2013-02-12 2014-08-21 Ys Pharm Tech Epinephrine formulations for medicinal products
EP3041461A4 (en) 2013-09-03 2017-05-03 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
EP3082817A4 (en) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US20160051494A1 (en) 2014-08-21 2016-02-25 Mylan, Inc. Multi-dose medication kit for treating anaphylaxis
US20170079907A1 (en) 2015-09-18 2017-03-23 Insys Development Company, Inc. Sublingual Epinephrine Spray
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US11571384B2 (en) 2015-09-18 2023-02-07 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
US11517525B2 (en) 2015-09-18 2022-12-06 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
US11458091B2 (en) 2016-11-18 2022-10-04 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
WO2018195029A1 (en) 2017-04-17 2018-10-25 Insys Development Company, Inc. Epinephrine spray formulations
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法

Also Published As

Publication number Publication date
US11717571B2 (en) 2023-08-08
US20240024485A1 (en) 2024-01-25
US20190269781A1 (en) 2019-09-05
WO2019157099A8 (en) 2019-10-24
US10682414B2 (en) 2020-06-16
US11744895B2 (en) 2023-09-05
US11918655B2 (en) 2024-03-05
US20230302137A1 (en) 2023-09-28
US11191838B2 (en) 2021-12-07
JP2021193091A (ja) 2021-12-23
US20190269782A1 (en) 2019-09-05
US20190269780A1 (en) 2019-09-05
US20230085636A1 (en) 2023-03-23
WO2019157099A1 (en) 2019-08-15
US20210361770A1 (en) 2021-11-25
JP6941224B2 (ja) 2021-09-29
US20200261582A1 (en) 2020-08-20
JP2021508670A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
EA202091615A1 (ru) Интраназальные составы на основе эпинефрина и способы лечения заболевания
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CY1120950T1 (el) Θεραπεια ινωσης
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
SA516380290B1 (ar) نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
EA201892327A1 (ru) Ингаляционные и назальные бензодиазепины
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
EA202191067A1 (ru) Композиции и способы для лечения дефицита альфа-1-антитрипсина
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CO2018000171A2 (es) Metodos de purificacion y/o inactividad viral
UY38352A (es) Inhibidores de integrina alfavbeta6
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.
BR112021014566A2 (pt) Moduladores de gpr35
MX2018012250A (es) Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).